IP Library › Granted Patent US 7,758,873
Granted Patent B2
US 7,758,873 · App. 11/303,000 · Granted Jul 20, 2010

Polysaccharide containing botulinum toxin pharmaceutical compositions and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,758,873
App. No.
11/303,000
Granted
Jul 20, 2010
Kind
B2
Abstract

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.

Claims (18)

1. A method for reducing a skin wrinkle in a patient, the method comprising the step of administering to a dermal region of said patient which has said skin wrinkle, a therapeutically effective amount of a pharmaceutical composition comprising polysaccharides, albumin and a botulinum toxin, wherein the pharmaceutical composition comprises a first polysaccharide and a second polysaccharide, wherein the first polysaccharide has a molecular weight of from about 20,000 Daltons (D) to about 50,000 Daltons, and the second polysaccharide has a molecular weight of from about 500,000 Daltons to about 1,000,000 Daltons.

2. A method for reducing a skin wrinkle in a patient, the method comprising the step of administering to a dermal region of said patient which has said skin wrinkle, a therapeutically effective amount of a pharmaceutical composition comprising a first polysaccharide and a second polysaccharide, albumin and a botulinum toxin, wherein the first polysaccharide has a molecular weight of from about 20,000 Daltons (D) to about 50,000 Daltons, and the second polysaccharide has a molecular weight of from about 500,000 Daltons to about 1,000,000 Daltons and wherein the first polysaccharide comprises a disaccharide.

3. A method for reducing a skin wrinkle in a patient, the method comprising the step of administering to a dermal region of said patient which has said skin wrinkle, a therapeutically effective amount of a pharmaceutical composition comprising a polysaccharide, albumin and a botulinum toxin, wherein the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.

4. A method for reducing a skin wrinkle in a patient, the method comprising the step of administering to a dermal region of said patient which has said skin wrinkle, a therapeutically effective amount of a pharmaceutical composition comprising a polysaccharide, albumin and a botulinum toxin, wherein the polysaccharide is an ethyl ether substituted polysaccharide.

5. A method for reducing a skin wrinkle in a patient, the method comprising the step of administering to a dermal region of said patient which has said skin wrinkle, a therapeutically effective amount of a pharmaceutical composition comprising a polysaccharide, albumin and a botulinum toxin, wherein the polysaccharide comprises a plurality of linked glucopyranose units, each glucopyranose unit having a plurality of hydroxyl groups, wherein an average of about 6 to about 9 of the hydroxyl groups present on each 10 of the glucopyranoses present in the polysaccharide are substituted, through an ether linkage, with a compound of the formula (CH 2 ) n -OH, where n can be an integer from 1 to 4.

6. The method of claim 5 wherein the skin wrinkle comprises a glabellar line.

7. The method of claim 5 wherein the composition further comprises a collagen.

8. The method of claim 5 , wherein the botulinum toxin is botulinum toxin type A.

9. The method of claim 1 , wherein the skin wrinkle comprises a glabellar line.

10. The method of claim 1 , wherein the composition further comprises a collagen.

11. The method of claim 4 wherein the skin wrinkle comprises a glabellar line.

12. The method of claim 4 wherein the composition further comprises a collagen.

13. The method of claim 1 wherein the botulinum toxin is botulinum toxin type A.

14. The method of claim 4 wherein the botulinum toxin is botulinum toxin type A.

15. The method of claim 1 , wherein the composition further comprises an amino acid.

16. The method of claim 3 , wherein the composition further comprises an amino acid.

17. The method of claim 4 , wherein the composition further comprises an amino acid.

18. The method of claim 5 , wherein the composition further comprises an amino acid.